Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | BTK | Q06187 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320422 | 0.77 | JAK2 (0.41) | JAK2BTKMAPTTP53LMNA | |
| SCHEMBL16131507 | 0.71 | MAPT (0.56) | MAPTTP53LMNAL3MBTL1CMA1 | |
| SCHEMBL25749363 | 0.70 | MAPT (0.56) | MAPTTP53LMNACMA1HDAC8 | |
| SCHEMBL16334468 | 0.70 | BTK (0.71) | JAK2BTKMAPTLMNAKDM4E | |
| SCHEMBL16333864 | 0.70 | BTK (1.00) | JAK2BTKMAPTNPC1 | |
| SCHEMBL27976634 | 0.69 | CHRNB2 (0.48) | MAPTTP53LMNAL3MBTL1HDAC8 | |
| SCHEMBL10019341 | 0.69 | MAPT (0.47) | MAPTTP53LMNACMA1HDAC8 | |
| SCHEMBL5480233 | 0.69 | HTR6 (0.43) | MAPTTP53LMNAL3MBTL1NPC1 | |
| SCHEMBL15873794 | 0.68 | CMA1 (0.41) | JAK2BTKL3MBTL1CMA1HDAC6 | |
| SCHEMBL26121258 | 0.66 | MAPT (0.48) | MAPTTP53LMNAL3MBTL1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3013814-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | JAK2 3/4885BTK 1/4885MAPT 4755/4885 |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | JAK2 3/4885BTK 1/4885MAPT 4755/4885 |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | JAK2 3/4885BTK 1/4885MAPT 4755/4885 |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | JAK2 3/4885BTK 1/4885MAPT 4755/4885 |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | JAK2 3/4885BTK 1/4885MAPT 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.